Results 11 to 20 of about 159,964 (350)

Global, regional, and national burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2019

Frontiers in Medicine
ObjectivesOur aim was to explore the disease burden caused by gallbladder and biliary tract cancer globally, regionally, and nationally, by age and sex.MethodsThe absolute number of cases and age-standardized rates (ASR) of incidence, prevalence ...
Jiao Su, Yuanhao Liang, Xiaofeng He
doaj   +2 more sources

Causal relationship between immune cell phenotypes and risk of biliary tract cancer: evidence from Mendelian randomization analysis

Frontiers in Immunology
BackgroundBiliary tract cancer stands as a prevalent illness, posing significant risks to human health, where immune cells are pivotal in both its development and recovery processes.
YaLan Hu, Kui Wang, Kui Wang, Yuhua Chen, Yongli Jin, Qiang Guo, Hui Tang   +6 more
doaj   +2 more sources

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA) [PDF]

Journal of hepato-biliary-pancreatic sciences, 2022
Gemcitabine/cisplatin (GC) combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). No randomized clinical trials have been able to demonstrate the survival benefit over GC during the past ...
Tatsuya Ioka, Masashi Kanai, Shogo Kobayashi, Daisuke Sakai, Hidetoshi Eguchi, Hideo Baba, Satoru Seo, Akinobu Taketomi, Tadatoshi Takayama, Hiroki Yamaue, Masahiro Takahashi, Masayuki Sho, Keiko Kamei, Jiro Fujimoto, Masanori Toyoda, Junzo Shimizu, Takuma Goto, Yoshitaro Shindo, Kenichi Yoshimura, Etsuro Hatano, Hiroaki Nagano, Kansai Hepatobiliary Oncology Group (KHBO)   +21 more
openalex   +2 more sources

Robotic Surgery for Biliary Tract Cancer [PDF]

Cancers, 2022
Simple Summary Complete surgical resection of biliary tract cancer provides the best chance at long-term survival. These surgeries are complex and can be associated with high morbidity and prolonged recovery. Minimally invasive approaches have been shown
Lyonell B. Kone, Philip Bystrom, Ajay V. Maker   +2 more
openalex   +2 more sources

Development and Validation of a Prognostic Nomogram Based on the Systemic Immune-Inflammation Index for Resectable Gallbladder Cancer to Predict Survival and Chemotherapy Benefit

Frontiers in Oncology, 2021
ObjectivesTo investigate the prognostic significance of the systemic immune-inflammation index (SII) in patients after radical cholecystectomy for gallbladder cancer (GBC) using overall survival (OS) as the primary outcome measure.MethodsBased on data ...
Lin Li, Lin Li, Lin Li, Lin Li, Tai Ren, Tai Ren, Tai Ren, Ke Liu, Ke Liu, Ke Liu, Ke Liu, Mao-Lan Li, Mao-Lan Li, Mao-Lan Li, Ya-Jun Geng, Ya-Jun Geng, Ya-Jun Geng, Ya-Jun Geng, Yang Yang, Yang Yang, Yang Yang, Yang Yang, Huai-Feng Li, Huai-Feng Li, Huai-Feng Li, Xue-Chuan Li, Xue-Chuan Li, Xue-Chuan Li, Xue-Chuan Li, Run-Fa Bao, Run-Fa Bao, Run-Fa Bao, Yi-Jun Shu, Yi-Jun Shu, Yi-Jun Shu, Hao Weng, Hao Weng, Hao Weng, Wei Gong, Wei Gong, Wei Gong, Wan Yee Lau, Xiang-Song Wu, Xiang-Song Wu, Xiang-Song Wu, Ying-Bin Liu, Ying-Bin Liu, Ying-Bin Liu, Ying-Bin Liu   +48 more
doaj   +1 more source

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

Liver international (Print), 2023
The TOPAZ‐1 phase III trial reported a survival benefit with the anti‐programmed death cell ligand 1 (anti‐PD‐L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer.
M. Rimini, L. Fornaro, S. Lonardi, M. Niger, D. Lavacchi, T. Pressiani, J. Lucchetti, G. Giordano, A. Pretta, E. Tamburini, C. Pirrone, I. Rapposelli, A. Diana, E. Martinelli, I. Garajová, Francesca Simionato, M. Schirripa, V. Formica, C. Vivaldi, E. Caliman, M. Rizzato, Valentina Zanuso, F. Nichetti, L. Angotti, M. Landriscina, M. Scartozzi, M. Ramundo, A. Pastorino, B. Daniele, Noemi Cornara, M. Persano, Eleonora Gusmaroli, Riccardo Cerantola, F. Salani, F. Ratti, L. Aldrighetti, S. Cascinu, L. Rimassa, L. Antonuzzo, A. Casadei‐Gardini   +39 more
semanticscholar   +1 more source

Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study

Journal of Clinical Oncology, 2023
PURPOSE To evaluate the efficacy and safety of tucatinib and trastuzumab in patients with previously treated human epidermal growth factor receptor 2–positive (HER2+) metastatic biliary tract cancer (mBTC).
Y. Nakamura, N. Mizuno, Y. Sunakawa, J. Canon, M. Galsky, E. Hamilton, H. Hayashi, G. Jerusalem, Seung-Tae Kim, Keun-Wook Lee, L. A. Kankeu Fonkoua, B. Monk, D. Nguyen, Do-Youn Oh, A. Okines, David M. O’Malley, P. Pohlmann, Martin Reck, Sang Joon Shin, Kazuki Sudo, Shunji Takahashi, C. van Marcke, Evan Y. Yu, R. Groisberg, J. Ramos, Sherry Tan, Thomas E. Stinchcombe, T. Bekaii-Saab   +27 more
semanticscholar   +1 more source

Case report: A de novo ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib

Frontiers in Oncology, 2023
BackgroundGallbladder cancer (GBC) is highly lethal and resistant to most chemotherapeutic drugs. GBC was reported to carry multiple genetic mutations such as TP53, K-RAS, and ERBB2/3.
Jing-Xiao Yang, Zi-Yao Jia, Fa-Tao Liu, Wen-Guang Wu, Xue-Chuan Li, Xue-Chuan Li, Xue-Chuan Li, Lu Zou, Lu Zou, Lu Zou, Huai-Feng Li, Huai-Feng Li, Huai-Feng Li, Fei Zhang, Fei Zhang, Fei Zhang, Run-Fa Bao, Run-Fa Bao, Run-Fa Bao, Shu-You Peng, Wan Yee Lau, Yun Liu, Mao-Lan Li, Ying-Bin Liu, Ying-Bin Liu, Ying-Bin Liu   +25 more
doaj   +1 more source

The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study 2017

Cancer, 2021
The global burden of gallbladder and biliary tract cancer (GBTC) is increasing. A comprehensive evaluation of the burden is crucial to improve strategies for GBTC prevention and treatment.
Guoqing Ouyang, Qiang Liu, Yongrong Wu, Zhen Liu, Wuchang Lu, Shuai Li, Guangdong Pan, Xiang Chen   +7 more
semanticscholar   +1 more source

Exosomal MicroRNA signature acts as an efficient biomarker for non-invasive diagnosis of gallbladder carcinoma

iScience, 2022
Summary: Through a three-step study that relies on biomarker discovery, training, and validation, we identified a set of five exosomal microRNAs (miRNAs) that can be used to evaluate the risk of gallbladder carcinoma (GBC), including miR-552-3p, miR-581,
Pinghua Yang, Fengliang Song, Xinwei Yang, Xingzhou Yan, Xinyu Huang, Zhengjun Qiu, Zhijian Wen, Chi Liang, Xianglei Xin, Zhengqin Lei, Kecheng Zhang, Jue Yang, Hu Liu, Hongcheng Wang, Shijun Xiang, Liang Li, Baohua Zhang, Hongyang Wang   +17 more
doaj   +1 more source